Across TCGA pan-cancer cohorts, RFNG Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated RFNG data layer compared with 25 for mass-spec protein and 1 for mass-spec protein.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher RFNG Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RFNG expression acts as an unfavorable survival marker.
HNSC are the cancer types where RFNG Mutation most reproducibly stratifies survival.